Adamax

The draft was close to compliant: no personal, therapeutic or benefit claims, no reader address, no dosing, no em or en dashes, Australian English, and it ended with a research-use-only line. The main weaknesses were plainness (it led with the term neuropeptide and technical phrasing like brain-signalling and neuropeptide signalling before saying anything a normal person recognises) and mild jargon repetition. I refined both fields to lead in plain language, name the research areas people actually care about (focus and memory research, and how nerve cells communicate), keep the neuropeptide explanation as a simple aside rather than the lead, and preserve full compliance. The FINAL version I return is fully compliant, so isCompliant is true. It makes no claim about treating, improving, boosting or doing anything for a reader or their body, never addresses the reader, gives no dosing or protocol, frames the appeal purely as the research area, uses Australian English, contains no em or en dashes, and ends with a research-use-only line.